Background. Cancer is a major cause of morbidity and mortality, and colorectal cancer (CRC) is the third most common cancer in the world. The estimated costs of CRC treatment vary considerably, and if CRC costs in a model are based on empirically estimated total costs of stage I, II, III, or IV treatments, then they lack some flexibility to capture future changes in CRC treatment. The purpose was 1) to describe how to model CRC costs and survival and 2) to validate the model in a transparent and reproducible way. Methods. We applied a semi-Markov model with 70 health states and tracked age and time since specific health states (using tunnels and 3-dimensional data matrix). The model parameters are based on an observational study at Oslo University Hospital (2049 CRC patients), the National Patient Register, literature, and expert opinion. The target population was patients diagnosed with CRC. The model followed the
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C
ancer is a major cause of morbidity and mortality in the Western world, and colorectal cancer (CRC) is the second most common cancer in women and third in men. 1 The 5-year relative survival rates is 47% in Europe and 60% in the US. 2 The economic burden of cancer is expected to increase in the future, partly due to changing demographics and the introduction of new and resource-demanding treatments and screening methods. Thus, it is important to monitor the clinical course of cancer in patient cohorts to estimate cancer costs and develop sound methods to evaluate different treatment and screening regimens.
During the last decades, several models have been developed with an emphasis on describing and modeling the preclinical course of cancer. [3] [4] [5] [6] [7] [8] A workshop among leading academic teams concluded that there was considerable variation in cost estimates used in the various models and that future research should address modeling costs both more precisely and more transparently. 9 This limitation was confirmed in a review of economic evaluations of laparoscopic surgery. 10 Compared with estimating the cost of CRC treatment empirically, using model-based estimates has several advantages. [11] [12] [13] [14] Within a model framework, it is easier to adjust for changes like mortality rates, recurrence rates, and new treatments. Further, a model facilitates extrapolations of both costs and outcomes, allowing predictions 10-30 years into the future.
The model presented in this paper is similar to the model of Tilson and others 15 but has some extensions. First, time is defined explicitly by using a Markov framework instead of decision trees. A 3-dimensional data matrix captures time dependence according to the age of the patient and how long he or she has remained in a defined health state. Several other extensions were included in relation to 1) independent costs according to exclusively local recurrence, distant recurrence only, or a combination of local and distant recurrence; 2) survival and cost of treatment for re-recurrence, which is defined as a new recurrence after an apparently curative treatment of the first recurrence; 3) a separate decision tree for palliative chemotherapy; 4) side effects from surgery; and 5) (neo) adjuvant and palliative therapy.
To improve confidence in models, attention has been paid to transparency and validation. [16] [17] [18] The purpose of this paper was to contribute to modeling CRC cost and survival by presenting a transparent model and validating it. The structure of the Markov model was specified in detail, explaining how different data sources were used to estimate costs and transition probabilities. We validated the model according to standard methods in order to show the precision of the model. 18 The model was intended to be ''multiply applicable'' (general) so it could address a range of problems related to CRC treatment (surgery, chemotherapy, radiation, screening, lifestyle changes, etc.) and to be transferable to other countries that have access to a similar type of data.
THE MODEL Model Structure and Flow of CRC Patients
The main outcomes of the model were recurrence, survival, and costs of CRC, which were estimated by means of a semi-Markov model. [16] [17] [18] [19] [20] The model structure was based on literature about CRC treatment and the natural history of CRC, national guidelines on CRC treatment, and expert opinion (oncologist, colorectal surgeon, and gastro physician). Figure 1 illustrates the Markov model with mutually exclusive health states (squares) and how patients could move between the health states. The model simulates the flow of a 70-year-old cohort of CRC patients from the year of diagnosis through periods of treatment and health states without CRC symptoms, until they died from CRC or other causes or were 100 years old (red lines). The length of 1 cycle was defined as 1 year. Each arrow was represented by a transition probability. Loop arrows illustrate health states where the patient can stay for more than 1 year.
The TNM system, which classifies disease as stages I-IV, was used to stage the disease at the time of diagnosis (see definition in Appendix 1).
In the model, standard half-cycle corrections were applied to adjust for mortality. 21, 22 For costs, halfcycle corrections were not explicitly modeled but were performed indirectly, as the empirical data used to estimate CRC treatment costs consider compliance and mortality.
Algorithms and Modeling of Treatment and Disease Course
Primary treatment. The cohort entered the model in one of the TNM stages of year 0 when diagnostic and supplementary examinations were performed to establish disease stage, comorbidity, and the patient's general condition. Based on this workup, it was decided whether the treatment intention was curative or palliative. Curative treatment always implied resection of the primary tumor and regional lymph nodes, with or without pre-or postoperative radiotherapy and/or chemotherapy. After the histopathological report was finished, TNM staging and R (Residual tumor) classification were done. The treatment was defined as curative (called R0 resection) if the entire tumor was resected, there was no microscopic invasion of the resection margins, and there was no radiological evidence of residual tumor in other organs (no distant metastasis).
In the model, according to the primary treatment (year 0), the patients could go to ''disease free'' (DF) after a R0 resection or receive palliative treatment (or no treatment) if curative treatment was not possible. Palliative treatment included R1-2 resections and other palliative surgical procedures and/or (radio-) chemotherapy. Subsequently, the patients could die within 30 days after the operation (often due to treatment complications that resulted in the classification of CRC death), die later of CRC or causes other than CRC, or develop a recurrence for which some would receive treatment. A proportion of the patients started palliative chemotherapy during primary treatment and moved to further palliative chemotherapy the following years (years 2, 3, and 4 in palliation).
Follow-up and treatment of recurrence. From years 1 to 4 in the DF state after primary resection, the patients entered follow-up programs that varied according to the estimated risk of relapse and the national guidelines. From the point of DF, the patient could move to the next year in the DF state, could die (of CRC or other causes), or could have a recurrence, a local recurrence (LR), metastasis (distant recurrence [DR]), or a combination of LR and DR (local and distant recurrence, LDR).
The model principles behind the recurrence stages were similar to the treatment pattern based on the primary diagnosis. The patient would stay in the recurrence state for 1 cycle and receive treatment independent of whether the intention was curative. In the following cycle, the patient moved to DF after LR, DR, or LDR; died (of CRC or other causes); or moved on to palliative treatment. It was assumed that after a diagnosis of recurrence, the course of the individual patient would be identical to that of all other individuals with the same type of recurrence and independent of the TNM stage at the time of primary diagnosis.
Survival and Mortality
In the model, mortality was dichotomized according to cause of death-mortality caused by CRC (disease-specific mortality) or any other cause (allcause mortality exclusive of CRC mortality). Patients might die after surgery (\30 days); during palliative treatment followed by a terminal phase, whether due to CRC or the palliative treatment; or from an unrelated cause in any of the health states defined, including a DF state. Dying from CRC within the DF state is a correction for the patients who die from CRC within a month after diagnosis or for cases where the CRC is detected after the time of death (autopsy). Therefore, no CRC treatment costs created by recurrence are included for these patients. This correction comprises from 0.07% (stage I) to 0.7% (stage IV) of the patients every year.
Tunnel States
Probabilities for recurrence and death often depend on the duration of clinical disease, that is, the time from diagnosis. This time dependency (memory) was captured in the model by using ''tunnel states.'' 19, 20 By using tunnels, we can incorporate heterogeneity and simultaneously estimate survival and costs according to age groups. Including age is important when one is evaluating interventions like screening or primary prevention where the individual can be diagnosed with cancer and enter the model at any age.
All the DF after primary resection (light blue in Figure 1 ), DF after recurrence, and the 3 ''palliative'' states were parts of tunnels. The DF tunnels begin in year 1 after primary treatment and are continuous throughout year 10 (cycle 11).
Perspective and Cost
The model has the perspective of the health care payer. The CRC treatment costs included in-hospital CRC treatment (including diagnostics), treatment for complications, treatment of recurrence, radiation and chemotherapies, follow-up, and patient visits to a general practitioner.
To estimate the cost in each health state, submodels were used to reflect the treatment pathways. The unit cost of the different treatments was mainly based on the reimbursement systems in Norway.
The Hospitals in Norway were reimbursed partly by block grants and partly through fees for service. The fee-for-service component was directly linked with diagnosis-related groups (DRGs).* The unit cost for the chemotherapy drug is based on Oncolex y estimates.
To determine cost, frequency, and compliance with follow-up and surveillance, we applied market prices, data from Kørner and others, 23 and the national guidelines for CRC treatment. 24 For palliative chemotherapy treatment, a decision tree was used to estimate costs according to treatment paths and was then distributed according to the treatment years in the Markov model. For each treatment in the decision tree, a separate cost model was developed, which took into account the cost of the drug, computed tomography scanning, complications, and the time spent on therapy by the nurse, pharmacist, and medical practitioner. The model corrected for noncompliance and discontinuation of chemotherapy.
Data Source
Inputs were based on Norwegian data as far as possible. An important source was an observational study in the period 1993-2010 of 2049 patients diagnosed with CRC at Oslo University Hospital-Aker (referred to as the OUS data). 25, 26 The OUS data included a wide range of variables related to CRC treatment (mostly surgical procedures) and time to recurrence and death.
Information from the National Patient Register (referred to as the NPR data), based on data related to an analysis by Aas, 27 was used to quantify some types of treatments from the years 2003 and 2004. The NPR data were collected for 2 counties in Norway and should be representative of the general population. There have been differences in CRC risk between regions in Norway. Around the year 2000, the relative risk of CRC for inhabitants in these 2 counties was close to 1.0 compared with the overall national risk.
Other data sources were national life tables, international scientific publications (e.g., overall survival of patients receiving palliative chemotherapy), and *In 2010, approximately 900 DRGs were used to reflect the hospital case mix. One DRG received a value reflecting the average cost of treating 1 patient. Each DRG received a weight reflecting the intensity of the treatment compared with treating the average patient.
y Oncolex is a Norwegian encyclopedia for oncology health personnel (www.oncolex.org). It includes background information and updated procedures for treatment of CRC. expert opinions in parameters considered not to have essential effects on outcome. Data for treatment after recurrence were limited and based on literature and expert opinion.
A Scandinavian prospective, population-based, observational study was an important data source concerning palliative chemotherapy. 28 Calibration is normally used as a complement to data sources, but it was concluded that calibration was not needed due to a good fit of the model.
VALIDATION OF THE MODEL
The model was validated according to face validity, internal and external validity, and crossvalidity. 29 We concentrated the validation on survival and the cost of CRC treatment, being the 2 main outcomes of the model. They are endpoint estimates of numerous intermediate calculations in the model and therefore indirectly also represent a rough test of the subparts of the model.
Face Validity
To determine face validity, we assess whether the results make sense and can be explained at an intuitive level. 29 The model structure, including health states, patient flow, and the data used, was closely evaluated by medical experts and could therefore easily be recognized. The estimates used for important cost components during the first year of treatment and during palliative treatment were based on established assumptions and classification of treatment options and their costs (see Appendix 1).
Internal Validity
Internal validity implies that the mathematical calculations were correct and consistent with the specification of the model. 29 Algorithms were used to check that the row of the data matrices for the annual transition probabilities summed to 1 and that the number of patients in the Markov model was constant for all cycles.
Validation of the economic model was more complicated. Extensive use of checking calculations was performed to test whether the results based on the model were replicable. Approximately 150 one-way sensitivity simulations were run to test whether the model behaved as expected (i.e., according to size, direction and symmetry). No anomalies were found.
Cross-Validity
For cross-validation or between-model validation, we compared models (or methods) that were independently developed, but aimed at estimating the same outcomes, to investigate whether they achieved similar results.
Overall survival. A 10-year overall survival estimated by the model was compared with statistical estimations (Weibull distribution, STATA) based on the OUS data ( Figure 2) . Overall survival was used as an endpoint because it reflected the sum of all moves, was not used directly as an input in the model, and was normally more reliable than the other relevant output measures.
In cross-validation, the degree of model and data independence is important. The higher the degree of independence, the more valuable is the validation. Independence is obtained if the models compared use completely different data sources and apply different types of methods. In the cross-validation, different methods were used but the data were partially dependent. In the model, OUS data were used to estimate disease-free survival and time to recurrence after primary treatment (for the patients who underwent R0 resection), while in the statistical analyses, data for all 2049 patients were used to estimate overall survival. In addition to the OUS data mentioned, the literature and expert opinions were used to find the R0 resection rate in patients with recurrent disease and to estimate the survival for patients in palliative treatment. A simplified model (based on a portion of the patients in the OUS data) was then developed to estimate disease-free survival after R0 resection for recurrence and time to rerecurrence.
The curves in Figure 2 indicate that the structure and assumptions of the model correspond well with the Weibull regression. Even without a preceding calibration of the model, the differences in survival between the 2 methods of estimation in the fifth year after diagnosis were -0.002, -0.002, 0.014, and -0.004 for stages I, II, III, and IV, respectively, and in the tenth year were -0.001, -0.018, -0.004, and 0.001, respectively. The areas between the curves (based on the model and the Weibull estimation) showed the difference in survival between the 2 methods and were 0.27, -0.22, 1.62, and -0.04 months, respectively. Over 10 years, the weighted difference was on average 11.5 days (0.38 months) for all stages.
The curves based on the model for stages I, II, and III overestimated the survival during the first years. This seemed to be caused by structural elements in the model due to a mortality lag. A DF patient with a recurrence death within 12 months was not defined as dead during that cycle according to the model (except for a small fraction who would die before knowing about the recurrence) but was rather moved to one of the health states of treatment for recurrence. This could also explain why stage I patients have the smallest deviation (lowest recurrence) and stage III the greatest, with stage II in between. We could reduce this problem by shortening the cycles from 12 to 6 months or even 1 month. Furthermore, the model underestimated the survival curve for stage II in the last part of the 10-year period (Figure 2 ). The reasons seemed partly to be that patients in stage II were relatively more often struck by isolated local recurrence than the average CRC patient, and patients with local recurrence survived for a longer time than patients who experienced DR or LDR, while the model assumed the same survival time for all 3 types of recurrence.
The good fit between the statistical estimations and the simulation model of the 40 estimates of comparison indicated that the structure seemed to be close to reality and captured the true treatment pathways.
From cycle 11, after completing the DF tunnel, the patient was assumed to have no recurrence. For this part of the model, the overall mortality was based mainly on data from the Norwegian Life Table. To verify consistency with natural survival for the Norwegian population, estimated overall survival from the model was validated against the life table for patients aged 70-100 years.
As expected, none of the overall survival curves of the 4 stages cross, none of these cross the overall survival curve based on the National Life Table, and the curves show a gradual change (Figure 3) . The data used were partly dependent in this validation, because the life table was also used in the model as part of the background mortality from cycle 11 or when the cohort was 81 years of age (year 11 in Figure  3 ). Another weakness in this validation was the expected difference between the natural survival of the general population used in the model and the expected background survival for the CRC group. The latter group seemed to have a lifestyle that increased the risk of death apart from CRC. [30] [31] [32] [33] CRC treatment costs. Comparing our CRC costs with a non-Norwegian study is difficult as a result of often major differences related to time horizon of costs, treatment regimens, unit costs, general health conditions, and whether the cost of recurrence and Figure 2 Model means the overall survival curve simulated by the model, and Weibull means the overall survival curve estimated with Weibull distribution using our data from Oslo University Hospital.
palliative treatment was included. In addition, diagnostics, treatment regimens, and cost can change significantly over time. Nevertheless, we compared our results with a recent Irish study that thoroughly described the treatment regimen and other important conditions so that we could correct for the differences in the assumptions of the Irish study and our study. 15 The study published by Tilson and others 15 was a model study (decision trees) based on 4268 CRC patients (National Cancer Registry Ireland, [2004] [2005] , local hospitals' databases and protocols, literature, and expert clinical opinions. The Irish model was developed independently from ours with regard to both data and structure.
Our model estimated the total lifetime CRC costs to be as follows: for stage IV patients, e61,396; for stage III patients, e49,894; for stage II patients, e33,501; and for stage I patients, e23,386 (average 2011: 1 Euro = 7.79 NOK and 1 Euro = 1.39 USD). When corrected for the exchange rate (8.19%, average 2008-2011 ) and annual inflation (3.4%, average Irish Consumer Price Index for health 2008-2011, see www.cso.ie), the costs for stages I, II, and III in Ireland were 17.7%, 26.7%, and 13.8% higher, respectively, than in our model, while stage IV was 30.7% lower. There were some important differences in prices and treatment regimens between the studies.
z After we adjusted for these factors in our model, the cost differences between Tilson and others'
15 model and our model (Tilson's model minus our model) were -3.0%, -1.3%, 3.6%, and -1.2% for stages I, II, III, and IV, respectively. These 4 deviations were all within the estimated confidence interval in the study of Tilson and others, which varied between 612% and 29% of the stage cost estimates.
External Validation
External validation compares actual event data with the result from a model simulating the same scenario. For a multi-application model like ours, validation could be general or could be specific to each application of the model. ''External validation and predictive validation are critical as they most closely correspond to the model's purpose-to help decision makers anticipate what will occur if they take certain actions.'' 18(p738) Figure 3 Overall survival for the Norwegian population (without colorectal cancer [CRC]) and for CRC patients according to the disease stage.
z Tilson and others 15 assumed higher prices for resections for both the colon and rectum; less use of palliative chemotherapy; less use of adjuvant chemotherapy for stage III; no recurrence for stage I; a cost for recurrence equal to the cost of stage IV; and no category given for 'nonsurgical supportive treatment and care' except best supportive care.
Relative survival. The first external validation was done by comparing relative survival estimated by the model with patients monitored by the Cancer Registry of Norway, which monitors the whole Norwegian population (about 5 million), while our OUS data were based on a catchment area of about 4.2% of the total population. Further, as the Cancer Registry of Norway organizes the data differently from the OUS data, the 2 data sources were highly independent.
In Figure 4 , the comparison revealed a 3.9% higher relative survival for the model during the first year and 0.9%, 5.6%, and 5.6% lower relative survival 5, 10, and 15 years after diagnosis. As observed for the cross-validation, this external validation showed that the model predictions were too high immediately after diagnosis, rather accurate after 5 years, and slightly lower at year 10. Fifteen years after diagnosis, the validation indicated that the difference had stabilized between 5% and 6%.
The overestimation of survival up to 5 years after diagnosis can partly be explained by 1-year cycles, as argued above. The general picture beyond 5 years was a higher mortality in our model. One possible explanation might be that our statistical analyses were based on older data (1993-2010), while the analyses from the Cancer Registry of Norway displayed relative survival estimates for the follow-up period 2008-2010. According to the Cancer Registry of Norway, relative survival has increased gradually during the last decades.
CRC treatment costs.
In an external validation with a relevant population, total costs were compared with empirically estimated (''model-free'') total costs based on a Norwegian population study by Aas. 27 The methods used for estimation in the 2 studies were therefore highly independent, although for 16% of the treatments, the 2 studies used the same data source (NPR data), but these data were collected from different time periods.
Adjusted for the annual price change of the Norwegian DRGs, the estimated CRC costs reported by Aas 27 were e29,890 for all patients (2011 Euro) in the control group with no screening, while the model estimate was e41,548 (39.0% higher). This difference could partly be explained by the increased intensity of palliative treatment in the period between Aas's study (1999) (2000) (2001) and our study (2010) (2011) . In 1999-2001, biological agents were rarely used in Norway. In addition, the use of radiation therapy and surgery for metastases was not included in Aas's study. When adjusting for these two, as well, the model result was 9.1% higher than the estimate by Aas. Furthermore, taking into account Aas's estimated costs for a 5-year period, the model estimate was 3.1% higher than Aas's model-free estimate. Additionally, corrections due to different follow-up schemes for the Figure 4 External validation between the model and data from the Cancer Registry of Norway.
2 periods must be made. Our model was based on the Norwegian guidelines from 2010, while Aas's study was based on the actual follow-up years 1999-2001. 24 If we instead use the guidelines from that period, the model estimate for the average CRC cost was 1.3% higher than the model-free estimate.
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Both with and without this last correction, the model seems to fit well when taking into account that the lower and upper confidence interval for Aas's CRC cost estimate was 11%-12%.
DISCUSSION, APPLICATION, AND FURTHER IMPROVEMENTS
This study demonstrates a multi-application (general) model for estimating survival and costs for CRC patients. The validation of the model revealed a good match with reality both in survival and in costs. The model is suitable for addressing a wide range of CRCrelated themes, the most important being the estimation of cost and survival associated with different treatments and prevention measures. Such information is essential for future revisions of guidelines and health care providers.
Application of the Model
The following applications and advantages of the model should be emphasized. The model 1) estimates the costs and survival time of an average CRC patient according to different disease stages; 2) estimates final outcomes from changes in intermediate outcomes such as decline in both recurrence and mortality rate due to improvement in preoperative diagnostics; 3) can be used in economic evaluations by applying modest adjustments and developments needed to perform economic evaluations of different types of screening, prevention, introduction of new treatment, and follow-up alternatives; 4) estimates resource use; 5) can adjust for changed parameters over time (time-dependency) and simultaneously account for the time since CRC treatment, consequences of CRC patient age, alterations in treatment, and changes in cost and resource use over time (i.e., by using the 8 tunnels and the 3-dimensional data matrix); and 6) is transferable to other countries with access to the same types of data. Since calibration has not been used in this model, applying data from another country and building the model with the recommendations and assumptions provided in the present article and appendixes should, in principle, effect a similar goodness of fit. See more on applications in Appendix 2.
Weaknesses and Further Developments of the Model
The cycles in the model were set to 1 year, which to some extent restricts the precision of the model. Linearity is especially likely to be an unsatisfying approximation during the first year after a diagnosis of stage IV, the first year after a diagnosis of recurrence, and the first year of palliative treatment. The problem would be reduced if the cycles were reduced. One-month cycles could be incorporated into the model by changing the cycle lengths for all health states or by building separate sub-Markov models for selected health states, making the cycle length shorter (such as a cycle length of a week or a month) for the selected states, and retaining the 1-year cycle for the other health states. Shorter cycles would make the model more complex and would require more detailed data, which accentuates the tradeoff between model complexity and accuracy. Our plan for the next generation of this model is to include shorter cycles for some health states.
The OUS data range from 1993 to 2010. Since some of these data are relatively old, survival in the model is lower, which can be explained by the older and less effective treatments. These deviations are 0.9%, 5.6%, and 5.6% lower relative survival at 5, 10, and 15 years, respectively, after diagnosis when the model estimates are compared with data from the Cancer Registry of Norway (see the section ''Relative Survival'').
In the model, we used a cohort of patients diagnosed at the age of 70 years. This may have resulted in a higher survival rate than if we had used the average age in the OUS sample. The average age during stages I-IV at the time of diagnosis was 69.9, 72.3, 70.4, and 70.5 years, respectively. When we compared these average ages with our 70-year-old patients (based on Weibull regressions), we found that the differences in overall survival 10 years after diagnosis were -0.2%, 4.2%, 0.7%, and 0.03%, respectively, for the 4 stages. These differences are quite small and could only to some extent affect the external validation between the model and data from the Cancer Registry of Norway.
The palliative submodel was suitable for exploring treatment paths and costs, but there was no explicit, built-in time dimension. An approximation was therefore used to disperse the costs over time. A better solution could be to build a separate sub-Markov model with weekly or monthly cycles for palliation into the main model.
The model has 70 health states and 8 ''tunnels'' and uses a 3-dimensional data matrix to handle the changing rates of recurrence and mortality by age and year since primary CRC or recurrence. The complexity could be a drawback for decision makers to fully understand all the mechanisms of the model. Still, hardly any part of the model could be further simplified; quite the contrary seems to be the issue.
In the model, the OUS data were used as the basis for the survival analysis. Because the OUS data were collected over a long time period, it could imply that subgroups of patients are treated differently from current guidelines. Basing the inputs on newer data could adjust for these differences.
Many articles analyze the costs during the last year that patients are alive or for other time periods, but no relevant articles analyzing costs of the activity related to ''best supportive care'' were found. We assume, however, that this cost is partly included in ''digestive malignancy'' ( Table 7 , Appendix 1).
There seems to be a lack of data on the resource use related to treatment for local and distant recurrence, separately or combined, mainly because the relevant registers are not organized to estimate this. Solutions could be to conduct observational or retrospective studies on resource use after a recurrence or expand the registries to include such data.
In such general models as ours, external validations can be applied to some components of the model or to the model as a whole. 18 Our external validation was applied to the model as a whole by validating for the main outcomes: survival and cost. One problem with these could be that errors in different parts of the model may cancel out each other and in sum give a result for the model consistent with the external data. Future validations of the model should therefore also focus on different components of the model. Some of these could be certain categories of cost (e.g., palliative chemotherapy and treatment for metastasis), time to recurrence, and time to rerecurrence.
Our validations for survival were comparisons with observed data for survival rates at whole-year points. For future validations of the model, a suitable alternative to this approach could be life years or life expectancy.
Further development of the model should include quality of life and should elaborate on the palliative and re-recurrence part of the model. Including quality of life during primary treatment, treatment for recurrence, and palliative care would, to a greater extent, capture the severity according to the TNM stage.
The effect of CRC diagnosis on quality of life in the disease-free stages should also be considered.
